Previous 10 | Next 10 |
2023-10-09 11:04:43 ET More on 23andMe 23andMe: Hidden Therapeutics Asset 23andMe Is Too Far From Profitability 23andMe Holding Co. (ME) Q1 2024 Earnings Call Transcript 23andMe chief administrative officer acquires, sells shares 23andMe rises 17% on ...
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society...
2023-09-26 12:38:10 ET More on 23andMe Seeking Alpha’s Quant Rating on 23andMe Historical earnings data for 23andMe Financial information for 23andMe 23andMe: Hidden Therapeutics Asset 23andMe Is Too Far From Profitability For further d...
2023-09-14 16:53:50 ET Summary 23andMe's quarterly revenues have slightly decreased due to lower volumes sold, but there is still a market for its Personal Genome Service kit. The company has a massive data set that it is hoping to turn into usable therapies for various diseases. ...
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disease is common About one in 13 African Americans have the sickle cell trait. Many are una...
2023-09-10 04:07:56 ET Summary 23andMe's stock has declined significantly since its IPO, and the company is struggling to generate revenue from its business segments. The company's lack of profitability and cash flow issues raise concerns about its ability to sustain its business....
Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - Moneta Gold Inc. (TSX: ME) (OTCQX: MEAUF) (FSE: MOPA) ("Moneta" or the "Company") is pleased to announce a project update and assay results from thirty-two (32) drill holes on the Windjammer and Westaway deposits at the Tower Gold proje...
2023-09-01 06:34:45 ET Summary FDA clears 23andMe to report more genetic variants associated with higher risk of certain cancers. Bernstein says reclassifying cannabis as Schedule III not preferred outcome. UPS offers voluntary separation benefit to pilots, aiming for 167 pilo...
2023-08-31 18:50:04 ET More on 23andMe 23andMe: Revenue Growth And Secular Trend, But Lack Of Profits Makes It A Hold 23andMe down 3% on Q1 earnings, guidance revision 23andMe to cut roughly 9% of workforce, or about 75 employees 23 and Me fiscal 2024 revenue...
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these additional variants occur more often in people of African American and Hispanic/Latino de...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...